Skip to content

Treasury Stock at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$25.36B+19.2%
Zoetis logo
ZoetisZTS
$11.29B+43.1%
Danaher logo
DanaherDHR
$12.32B+32.4%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$1.01B+30.8%
Quest Diagnostics logo
Quest DiagnosticsDGX
$5.17B+8.4%
Abbott logo
AbbottABT
$16.94B+1.9%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Cash & equivalents$200.5M+22.3%
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$42.94B-5.8%
Enterprise value$43.31B-6.0%
P/E39.2×-7.0×
P/S9.7×-1.6×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's treasury stock?
Idexx Laboratories (IDXX) reported treasury stock of $6.93B in Q1 2026.
How has Idexx Laboratories's treasury stock changed year-over-year?
Idexx Laboratories's treasury stock increased by 20.5% year-over-year, from $5.75B to $6.93B.
What is the long-term trend for Idexx Laboratories's treasury stock?
Over 5 years (2020 to 2025), Idexx Laboratories's treasury stock has grown at a 18.6% compound annual growth rate (CAGR), from $2.8B to $6.56B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.